Gilead battles Congress, European regulators over hep C drug price By: San Francisco Business Times via Business Journals July 11, 2014 at 16:55 PM EDT Gilead Sciences Inc. is fighting on two regulatory fronts in its efforts to sell its $1,000-a-pill hepatitis C drug Sovaldi... Read More >>